Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 66 of 110 Updated Nov 17, 2026

PNC-27

p53-HDM2 binding peptide

PRECLINICAL · ANTICANCER PEPTIDE (EXPERIMENTAL)

▓ 27 indexed citations across PubMed (20), EuropePMC (7).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

27 citations across 2 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Selective membrane disruption of cancer cells via HDM2 binding

Researched effects

Selective cancer cell membrane disruption (preclinical)

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

Preclinical only

Known concerns

No completed human trials; safety unknown

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.

    Biomedicines · 2024 — REVIEWS · AUTHORITY 54.4

  2. Anti-cancer peptides from ras-p21 and p53 proteins.

    Current pharmaceutical design · 2011 — REVIEWS · AUTHORITY 53.1

  3. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

    Proceedings of the National Academy of Sciences of the United States of America · 2010 — RESEARCH ARTICLES · AUTHORITY 43.0

  4. HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.

    Annals of clinical and laboratory science · 2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  5. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.

    Annals of clinical and laboratory science · 2024 — RESEARCH ARTICLES · AUTHORITY 34.4

  6. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells †

    2024 — RESEARCH ARTICLES · AUTHORITY 34.4

  7. The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.

    Journal of molecular graphics & modelling · 2023 — RESEARCH ARTICLES · AUTHORITY 34.3

  8. P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma.

    2023 — RESEARCH ARTICLES · AUTHORITY 34.3

  9. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.

    Biomedicines · 2022 — RESEARCH ARTICLES · AUTHORITY 34.2

  10. Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis:

    Iranian journal of basic medical sciences · 2022 — RESEARCH ARTICLES · AUTHORITY 34.2

Full citation library

Year distribution

Reviews

2
  1. 1.

    Pincus MR, Silberstein M, Zohar N, Sarafraz-Yazdi E, et al. · Biomedicines · 2024 · PMID 38927351

    Recent advances in cancer treatment like personalized chemotherapy and immunotherapy are aimed at tumors that meet certain specifications. In this review, we describe a new approach to general cancer treatment, termed peptide-induced poptosis, in which specific peptides, e.g., PNC-27 and its shorter analogue, PNC-28, that contain the segment of the p53 transactivating 12-26 domain that bind to HDM-2 in its 1-109 domain, bind to HDM-2 in the membranes of cancer cells, resulting in transmembrane p…

  2. 2.

    Pincus MR, Fenelus M, Sarafraz-Yazdi E, Adler V, et al. · Current pharmaceutical design · 2011 · PMID 21728981

    We have employed computer-based molecular modeling approaches to design peptides from the ras-p21 and p53 proteins that either induce tumor cell reversion to the untransformed phenotype or induce tumor cell necrosis without affecting normal cells. For rasp21, we have computed and superimposed the average low energy structures for the wild-type protein and oncogenic forms of this protein and found that specific domains change conformation in the oncogenic proteins. We have synthesized peptides co…

Research Articles

25
  1. 3.

    Sarafraz-Yazdi E, Mumin S, Cheung D, Fridman D, et al. · Biomedicines · 2022 · PMID 35625682

    PNC-27, a 32-residue peptide that contains an HDM-2 binding domain and a cell-penetrating peptide (CPP) leader sequence kills cancer, but not normal, cells by binding to HDM-2 associated with the plasma membrane and induces the formation of pores causing tumor cell lysis and necrosis. Conformational energy calculations on the structure of PNC-27 bound to HDM-2 suggest that 1:1 complexes form between PNC-27 and HDM-2 with the leader sequence pointing away from the complex. Immuno-scanning electro…

  2. 4.

    Krzesaj P, Adler V, Feinman RD, Miller A, et al. · Annals of clinical and laboratory science · 2024 · PMID 38802154

    We have previously shown that the anti-cancer peptide PNC-27 kills cancer cells by co-localizing with membrane-expressed HDM-2, resulting in transmembrane pore formation causing extrusion of intracellular contents. We have also observed cancer cell mitochondrial disruption in PNC-27-treated cancer cells. Our objectives are to determine: 1. if PNC-27 binds to the p53 binding site of HDM-2 (residues 1-109) in the cancer cell membrane and 2. if this peptide causes selective disruption of cancer cel…

  3. 5.

    Krzesaj PK, Seydafkan S, Miller AI, Chen HT, et al. · Annals of clinical and laboratory science · 2025 · PMID 40750238

    The peptide PNC-27 has been found to kill many different endodermal solid tissue and hematopoietic cancer cells but has no effect on normal cells. The mechanism involves binding to the HDM-2 protein, which is expressed in the membranes of cancer cells but not in normal (untransformed) cells. Our objectives in the current study are to determine 1) if PNC-27 is lethal to squamous cervical epithelial cancer cells but not to untransformed squamous cervical cells; 2) if membrane-bound HDM-2 is expres…

  4. 6.

    Rahmani R, Darroudi M, Gharanfoli M, Chamani J, et al. · Iranian journal of basic medical sciences · 2022 · PMID 36311203

    Superparamagnetic iron oxide nanoparticles (SPIONs) have been considered promising non-invasive imaging tools in medicine. However, their high surface energy leads to NPs aggregation, while non-targeted SPIONs can cause cytotoxic effects on normal cells. In this work, we evaluated the Initially, PEI was conjugated to PNC-27 with HDM-2-binding domain. Then, SPIONs were loaded into PEI-PNC-27 through the ligand exchange method. The physicochemical characteristics of the synthesized NPs were evalua…

  5. 7.

    Thadi A, Lewis L, Goldstein E, Aggarwal A, et al. · Anticancer research · 2020 · PMID 32878773

    Anticancer peptide PNC-27 binds to HDM-2 protein on cancer cell membranes inducing the formation of cytotoxic transmembrane pores. Herein, we investigated HDM-2 membrane expression and the effect of PNC-27 treatment on human non-stem cell acute myelogenous leukemia cell lines: U937, acute monocytic leukemia; OCI-AML3, acute myelomonocytic leukemia and HL60, acute promyelocytic leukemia. We measured cell surface membrane expression of HDM-2 using flow cytometry. Cell viability was assessed using…

  6. 8.

    Davitt K, Babcock BD, Fenelus M, Poon CK, et al. · Annals of clinical and laboratory science · 2014 · PMID 25117093

    We have developed the anti-cancer peptide, PNC-27, which is a membrane-active peptide that binds to the HDM-2 protein expressed in the cancer cell membranes of solid tissue tumor cells and induces transmembrane pore formation in cancer, but not in normal cells, resulting in tumor cell necrosis that is independent of p53 activity in these cells. We now extend our study to non-solid tissue tumor cells, in this case, a primitive, possible stem cell human leukemia cell line (K562) that is also p53-h…

  7. 9.

    Alagkiozidis I, Gorelick C, Shah T, Chen YA, et al. · Annals of clinical and laboratory science · 2017 · PMID 28667027

    Paclitaxel is widely used in the treatment of gynecologic malignancies. It targets tumor cells in the M phase of the cell cycle. Cells in other phases survive the insult and repopulate the tumor. PNC-27 is a peptide synthesized of amino acids of the p53-MDM-2 binding domain. It kills various cancer cell lines in a dose-dependent manner. The goal of this study is to assess ovarian cancer cells' sensitivity to PNC-27 after surviving exposure to paclitaxel and to investigate the potential for syner…

  8. 10.

    Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E, et al. · Cancer chemotherapy and pharmacology · 2010 · PMID 20182728

    PNC-27, a peptide that contains an HDM-2-binding domain from p53 attached to a membrane-penetrating peptide on its carboxyl terminal end, is cytotoxic to cancer, but not normal, cells. It forms transmembrane pores in the cancer cell membrane. Our purpose is to determine if the whole peptide or critical fragments induce pore formation in cancer cells. We have prepared PNC-27 with a green fluorescent label on its amino terminus and a red fluorescent label on its carboxyl terminus and treated MCF-7…

  9. 11.

    Sarafraz-Yazdi E, Gorelick C, Wagreich AR, Salame G, et al. · Annals of clinical and laboratory science · 2015 · PMID 26663795

    Despite an 80% response rate to chemotherapy, epithelial ovarian cancer has the highest case fatality rate of all gynecologic malignancies. Several studies have shown the efficiency of anticancer peptides PNC-27 and PNC-28 in killing a variety of cancer cells selectively in vitro and in vivo. The purpose of this study was to evaluate the efficacy of PNC-27 against human primary epithelial ovarian cancer. We established primary cultures of freshly isolated epithelial ovarian cancer cells from pat…

  10. 12.

    Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, et al. · Proceedings of the National Academy of Sciences of the United States of America · 2010 · PMID 20080680

    The anticancer peptide PNC-27, which contains an HDM-2-binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain, has been found to kill cancer cells (but not normal cells) by inducing membranolysis. We find that our previously determined 3D structure of the p53 residues of PNC-27 is directly superimposable on the structure for the same residues bound to HDM-2, suggesting that the peptide may target HDM-2 in the membranes of cancer cells. We now find significan…

  11. 13.

    Bowne WB, Sookraj KA, Vishnevetsky M, Adler V, et al. · Annals of surgical oncology · 2008 · PMID 18931881

    PNC-27 and PNC-28 are p53-derived peptides from the human double minute (hdm-2) binding domain attached to penetratin. These peptides induce tumor cell necrosis of cancer cells, but not normal cells. The anticancer activity and mechanism of PNC-28 (p53 aa17-26-penetratin) was specifically studied against human pancreatic cancer. MiaPaCa-2 cells were treated with PNC-28. Necrosis was determined by measuring lactate dehydrogenase (LDH) and apoptosis as assayed for measuring elevation of proapoptot…

  12. 14.

    Thadi A, Morano WF, Khalili M, Babcock BD, et al. · Anticancer research · 2021 · PMID 33419797

    We have tested whether the anticancer peptide, PNC-27, that kills cancer cells but not normal cells by binding to cancer cell membrane HDM-2 forming pores, kills CD44+ colon cancer stem cells. Flow cytometry determined the CD44 and HDM-2 expression on six-colon cancer cell lines and one normal cell line (CCD-18Co). MTT, LDH release, annexin V binding and caspase 3 assays were used to assess PNC-27-induced cell death. Bioluminescence imaging measured PNC-27 effects on in vivo tumor growth. High p…

  13. 15.

    Wang H, Zhao D, Nguyen LX, Wu H, et al. · Leukemia · 2020 · PMID 31337857

    The E3 ligase human double minute 2 (HDM2) regulates the activity of the tumor suppressor protein p53. A p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs). Higher mHDM2 levels in AML blasts were associated with leukemi…

  14. 16.

    Thadi A, Gleeson EM, Khalili M, Shaikh MF, et al. · Annals of clinical and laboratory science · 2020 · PMID 33067207

    Patients with epithelial ovarian cancers experience the highest fatality rates among all gynecological malignancies which require development of novel treatment strategies. Tumor cell necrosis was previously reported in a number of cancer cell lines following treatment with a p53-derived anti-cancer peptide called PNC-27. This peptide induces necrosis by transmembrane pore formation with HDM-2 protein that is expressed in the cancer cell membrane. We aimed to extend these studies further by inve…

  15. 17.

    Soriano-Correa C, Vichi-Ramírez MM, Herrera-Valencia EE, Barrientos-Salcedo C · Journal of molecular graphics & modelling · 2023 · PMID 37086514

    Cancer is one of the leading causes of mortality in the world. Despite the existence of diverse antineoplastic treatments, these do not possess the expected efficacy in many cases. Knowledge of the molecular mechanisms involved in tumor processes allows the identification of a greater number of therapeutic targets employed in the study of new anticancer drugs. In the last decades, peptide-based therapy design using computational chemistry has gained importance in the field of oncology therapeuti…

  16. 18.

    Rosal R, Pincus MR, Brandt-Rauf PW, Fine RL, et al. · Biochemistry · 2004 · PMID 14967026

    We have recently found that a peptide from the mdm-2 binding domain of the p53 protein induced rapid membranolytic necrosis of a variety of different human cancer cell lines. To determine the role of solution structure in this peptide's selective and rapid tumor membrane disruptive behavior, we have performed two-dimensional NMR on a 32-residue sequence called PNC-27, in both an aqueous cytosolic-like and a mixed organic membrane-mimetic solution environment. In an aqueous milieu, PNC-27 contain…

  17. 19.

    Mokhtarzadeh A, Parhiz H, Hashemi M, Abnous K, et al. · Expert opinion on drug delivery · 2016 · PMID 26654047

    Targeted delivery of cytotoxic drugs or therapeutic antisense RNAs into specific cells is a major bottleneck in cancer therapy. To overcome this problem and improve the specificity for cancer cells, we describe a new-targeted delivery system using p53-derived peptides, namely PNC 27 and PNC 28. These peptides target HDM-2 on the surface of cancer cells. HDM-2 is overexpressed on the surface of cancerous cells, but not present on the untransformed cells. To determine HDM-2-expressing cells, we us…

  18. 20.

    Barrientos-Salcedo C, Arenas-Aranda D, Salamanca-Gómez F, Ortiz-Muñiz R, et al. · The journal of physical chemistry. A · 2007 · PMID 17472350

    PNC-27, a synthetic peptide, is derived from the TP53-HDM2 binding domain that include TP53 amino acids 12-26 linked with 17 amino acids from the antennapedia protein transference domain. This peptide induces membrane rupture in tumor cells through toroidal pores formation and has motivated several experimental studies; nonetheless, its mechanism of biological action remains unknown to date. Herein, we present a theoretical study at the Hartree-Fock and density functional theory (B3LYP) levels o…

  19. 21.
  20. 22.

    Niotis A, Tsiambas E, Dimitroulis D, Sarlanis H, Falidas E, Kavantzas N, Constantinides CA. · 2023 · PMID 37326394

    In the current molecular review, we describe the mechanisms of TP53/MDM2 deregulation and their impact on the colon adenocarcinoma molecular substrate and phenotype. Among the genes that are critically altered in carcinogenesis, the TP53 tumor suppressor gene is of major importance. The TP53 gene (gene locus: 17p13.1) regulates the cell cycle by controlling the G1/S and G2/M checkpoints securing the normal sequence of cell cycle phases. Furthermore, it is involved in apoptosis programmed cell de…

  21. 23.

    Bowne WB, Michl J, Bluth MH, Zenilman ME, Pincus MR. · 2007 · PMID 18007958

    We have employed a novel computer-based molecular modeling method to design peptides from the ras-p21 and p53 proteins that block proliferation of cancer cells. The rationale of our approach is to identify peptide domains from each protein that alter conformation in response to oncogenic amino acid substitutions in their polypeptide chain. We accomplish this by first generating and comparing low energy average structures for oncogenic and wild-type proteins using conformational energy calculatio…

  22. 24.

    Zhou M, Zou X, Cheng K, Zhong S, Su Y, Wu T, Tao Y, Cong L, Yan B, Jiang Y. · 2022 · PMID 35593206

    Due to the complex physiological structure, microenvironment and multiple physiological barriers, traditional anti-cancer drugs are severely restricted from reaching the tumour site. Cell-penetrating peptides (CPPs) are typically made up of 5-30 amino acids, and can be utilised as molecular transporters to facilitate the passage of therapeutic drugs across physiological barriers. Up to now, CPPs have widely been used in many anti-cancer treatment strategies, serving as an excellent potential cho…

  23. 25.

    Rodríguez V, Asenjo JA, Andrews BA. · 2014 · PMID 24885242

    <h4>Background</h4>Making peptide pharmaceuticals involves challenging processes where many barriers, which include production and manufacture, need to be overcome. A non common but interesting research area is related to peptides with intracellular targets, which opens up new possibilities, allowing the modulation of processes occurring within the cell or interference with signaling pathways. However, if the bioactive sequence requires fusion to a carrier peptide to allow access into the cell,…

  24. 26.

    Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, Rubinstein P, Visser J, Robinson R, Brandt-Rauf PW, Michl J, Fine RL, Pincus MR. · 2001 · PMID 11606716

    We have synthesized three peptides from the mdm-2 binding domain of human p53, residues 12-26 (PPLSQETFSDLWKLL), residues 12-20, and 17-26. To enable transport of the peptides across the cell membrane and at the same time to maximize the active mdm-2 binding alpha-helical conformation for these peptides, each was attached at its carboxyl terminus to the penetratin sequence, KKWKMRRNQFWVKVQRG, that contains many positively charged residues that stabilize an alpha-helix when present on its carboxy…

  25. 27.

    Yang H, Liu S, Cai H, Wan L, Li S, Li Y, Cheng J, Lu X. · 2010 · PMID 20484051

    The use of cell-penetrating peptides (CPPs) as drug carriers for targeted therapy is limited by the unrestricted cellular translocation of CPPs. The preferential induction of tumor cell death by penetratin (Antp)-directed peptides (PNC27 and PNC28), however, suggests that the CPP Antp may contribute to the preferential cytotoxicity of these peptides. Using PNC27 as a molecular model, we constructed three novel peptides (PT, PR9, and PD3) by replacing the leader peptide Antp with one of three dis…

Curated sources on file

2
  1. 1.
  2. 2.
    Note: Preclinical evidence only — no published human clinical trials. Cited paper describes in-vitro or animal-model mechanism.

Continue reading